Our Story
We are a 501(c)(3) nonprofit who provide a free, open-source, web-based application to help patients with catastrophic illnesses not well managed by the “standard of care” understand their clinical trial options.
Our unique search tool enables patient advocates from specific disease communities—including researchers, doctors, scientists, patients and caregivers—to curate relevant trials to help patients, caregivers, and care teams make informed treatment decisions.
Helping patients find and enroll in the best trials for them leads to both better patient outcomes and more successful trials and contributes to the advancement of medical innovation.
Our Team
Amy Westermann, MPH
Executive Director
Amy Westermann, MPH
Ms. Westermann joined ClinWiki in June 2019. She received her undergraduate degree from UC Berkeley in molecular and cell biology. She also holds a masters degree in public health from UCLA with a focus on health education. Most recently she came from the Pancreatic Cancer Action Network. There she quickly realized the need for more in-depth information on treatment options, especially clinical trials. While helping a family friend navigate through the process of finding a clinical trial, Ms. Westermann discovered the barriers to finding and enrolling in trials and wanted to make sure that other people have easier access to this information.
William Hoos, MS, MBA
Chairman
William Hoos, MS, MBA
Mr. Hoos is the founder of ClinWiki. His interest in clinical trials was sparked after watching his dad die from pancreatic cancer. This experience completely shifted his professional trajectory because he realized that there was a need for a platform like this. Mr. Hoos leveraged his professional experiences with medical innovation, diagnostics, pharmaceutical and patient advocacy to found ClinWiki in 2016. The ultimate goal of this organization is to increase access to clinical trial information for everyone so that there can be improved cancer outcomes.
Our Board Members
Kent Griffin, MBA
Managing Director, PHICAS Investors
Kent Griffin, MBA
Mr. Griffin is the Managing Director of PHICAS Investors and previously served as the President and Chief Operating Officer of BioMed Realty, a San Diego-based real estate investment trust focused on life science real estate in the United States and the United Kingdom, which was acquired by Blackstone in 2016. Previously he worked as an investment banker for JP Morgan and Raymond James. He began his career with Arthur Andersen as a CPA. He received a BS from Wake Forest University and an MBA from the University of North Carolina, Chapel Hill. Kent currently serves on the Boards of Directors of Healthpeak Properties and Cousins Properties. He serves on the Board of Advisors for Pilot Mountain Ventures and on various boards for the Wake Forest University School of Business, the Wood Center for Real Estate Studies at Chapel Hill, Charleston Waterkeeper and the Coastal Conservation League.
Matthew Harker, MBA, MPH
Deputy Director, Social Science Research Institute, Duke University
Matthew Harker, MBA, MPH
Currently Deputy Director, Social Science Research Institute at Duke University, Mr. Harker has over 17 years’ experience working with healthcare quality registries, technology platform support, clinical trials management, clinical practice administration, research operations, and policy implementation across several departments within Duke University and the Duke Clinical Research Institute (DCRI). Mr. Harker served in the US Air Force in supply chain logistics management and is a trained six sigma green belt. His background further extends into the fields of manufacturing, software and business consulting, and technology forecasting. Matthew works to address the information asymmetry that has created a Data Rich Information Poor environment for patients navigating the healthcare system and seeking clinical trial options. He connected with Mr. Hoos while working on the Clinical Trials Transformation Initiative (CTTI).
Grant Ingersoll, MS
Chief Technology Officer, Wikimedia Foundation
Grant Ingersoll, MS
Grant is the CTO of the Wikimedia Foundation and co-founder of Lucidworks, co-author of Taming Text, co-founder of Apache Mahout and a long-standing committer on the Apache Lucene and Solr open source projects. Grant’s experience includes engineering a variety of search, question answering, and natural language processing applications for a variety of domains and languages. He earned his BS from Amherst College in Math and Computer Science and his MS in Computer Science from Syracuse University.
Michael Kinch, PhD
Associate Vice Chancellor, Washington University at St. Louis
Michael Kinch, PhD
Dr. Kinch serves as Associate Vice Chancellor, Professor of Biochemistry and Molecular Biophysics, and Director, Centers for Research Innovation in Biotechnology and Drug Discovery at Washington University, St. Louis, MO. Previously, he was the Founder and Managing Director of the Yale Center for Molecular Discover, and served on the faculty of Johns Hopkins University in the School of Arts and Sciences. He served as Chief Scientific Officer and Vice President, Research and Development at Functional Genetics, Inc. and as the Head of the Departments of Cancer Biology and Translational Research and Senior Director of Research MedImmune, Inc. Dr. Kinch earned a BS in Molecular Genetics with Distinction in Immunology at The Ohio State University, a PhD in Immunology from Duke University Medical Center, and did his Post-Doctoral Fellowship at Lineberger Cancer Center at the University of North Carolina at Chapel Hill.
Deborah Morosini, MD, MSW
Executive Vice President and Chief of Clinical Affairs, Prelude Therapeutics
Deborah Morosini, MD, MSW
Dr. Morosini is Executive VP and Chief of Clinical Affairs for Prelude Therapeutics. She brings to Prelude extensive expertise in oncology drug development, clinical genomics, and philanthropic activism. She previously served as VP of Clinical Affairs and Patient Engagement at Loxo Oncology. Dr. Morosini played a key role in the launch of Vitrakvi® (larotrectinib) via a co-promote partnership with Bayer, and conducted launch preparations for LOXO-292. Prior to Loxo, she was an early team member at Foundation Medicine and previously founded and led the molecular pathology group at AstraZeneca Pharmaceuticals. She has served on numerous national oncology non-profit boards, and currently serves on the Scientific Advisory Board for Target Cancer and Upstage Lung Cancer. Dr. Morosini earned her BA in English from Mount Holyoke College, her MSW from NYU Graduate School of Social Work, and her MD from Boston University School of Medicine. She was chief resident and completed a pathology residency at Boston Medical Center.